HUMA Humacyte, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1818382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY52.5%
TTM net income YoY-156.3%
TTM EPS YoY-66.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-475.1%
Operating margin-4,602.9%
Net margin-3,955.1%
FCF margin-3,697.0%
EBITDA margin-4,381.8%
Returns
ROE-1,423.6%
ROA-87.3%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets85.6%
Debt / equity2.04x
Current ratio3.34x
Interest coverage-10.97x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue13.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.03M | $406,000 | $495,000 | $467,000 | $753,000 | $301,000 | $517,000 | $0 |
| Cost of revenue | $1.43M | $1.23M | $2.04M | $9.08M | $260,000 | $213,000 | $147,000 | $0 |
| Gross profit | -$401,000 | -$825,000 | -$1.54M | -$8.62M | $493,000 | $88,000 | $370,000 | $0 |
| R&D expense | $14.10M | $18.14M | $19.46M | $14.61M | $17.27M | $22.01M | $15.42M | $20.66M |
| SG&A expense | $9.01M | $8.03M | $7.93M | $7.62M | $7.61M | $7.81M | $8.14M | $7.43M |
| Operating income | -$23.52M | -$27.00M | -$28.93M | -$30.84M | -$24.39M | -$29.73M | -$23.18M | -$28.09M |
| Interest expense | $2.37M | $2.32M | $2.27M | $3.09M | $2.61M | $2.54M | $3.00M | $2.51M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.54M | -$36.80M | -$17.62M | -$24.80M | -$17.51M | -$37.66M | $39.14M | -$20.94M |
| EBITDA | -$22.24M | -$25.66M | -$27.59M | -$29.50M | -$23.09M | -$28.43M | -$21.88M | -$26.80M |
| EPS (basic) | -0.06 | -0.16 | -0.09 | — | -0.11 | -0.24 | 0.28 | — |
| EPS (diluted) | -0.06 | -0.16 | -0.09 | — | -0.11 | -0.24 | 0.28 | — |
| Weighted avg. shares (diluted) | 277.80M | 234.18M | 197.85M | — | 158.31M | 155.44M | 131.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $64.52M | $79.90M | $48.54M | $50.50M | $19.84M | $88.39M | $113.20M | $95.29M |
| Receivables | $811,000 | $330,000 | $434,000 | $441,000 | $1.08M | $394,000 | $488,000 | $0 |
| Inventory | $5.61M | $6.99M | $9.92M | $13.59M | $18.42M | $11.07M | $8.02M | $0 |
| Current assets | $82.68M | $92.79M | $63.60M | $67.80M | $41.35M | $51.73M | $73.70M | $47.86M |
| PP&E, net | $14.88M | $16.17M | $17.38M | $18.54M | $19.86M | $21.19M | $22.44M | $23.06M |
| Total assets | $125.57M | $138.09M | $110.56M | $116.37M | $91.51M | $138.79M | $162.55M | $137.87M |
| Current liabilities | $24.76M | $14.95M | $16.19M | $18.37M | $25.58M | $21.09M | $20.03M | $19.95M |
| Long-term debt | $36.80M | $36.32M | $35.87M | $35.44M | — | — | — | $0 |
| Total debt | $36.80M | $36.32M | $35.87M | $35.44M | — | — | — | $0 |
| Total liabilities | $107.51M | $106.83M | $98.93M | $113.26M | $96.26M | $134.74M | $126.51M | $190.54M |
| Shareholders' equity | $18.06M | $31.26M | $11.62M | $3.11M | -$4.75M | $4.05M | $36.04M | -$52.67M |
| Net debt | -$27.72M | -$43.58M | -$12.67M | -$15.05M | — | — | — | -$95.29M |
| Shares outstanding | 277.80M | 277.80M | 222.02M | 193.00M | 158.84M | 156.34M | 155.12M | 130.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$14.97M | -$22.06M | -$25.10M | -$26.12M | -$23.90M | -$26.41M | -$28.60M | -$26.58M |
| Capital expenditure | $0 | $104,000 | $175,000 | $39,000 | $49,000 | $568,000 | $228,000 | $63,000 |
| Free cash flow | -$14.97M | -$22.16M | -$25.28M | -$26.16M | -$23.95M | -$26.98M | -$28.83M | -$26.64M |
| Investing cash flow | $0 | -$104,000 | -$175,000 | -$39,000 | -$49,000 | -$568,000 | -$228,000 | -$63,000 |
| Financing cash flow | -$406,000 | $53.53M | $23.32M | $57.17M | -$44.59M | $2.17M | $46.74M | $51.01M |
| Depreciation & amortization | $1.28M | $1.34M | $1.34M | $1.34M | $1.30M | $1.30M | $1.31M | $1.28M |
| Stock-based compensation | $2.34M | $2.61M | $3.17M | $2.47M | $2.51M | $2.43M | $2.49M | $1.69M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.